RE: IP17 Jul 2025 20:20
This is pertinent information for investors to know and be prepared for. If a PMA is warranted, what is the plan to raise the proper funds?
The cost of obtaining Premarket Approval (PMA) for a Class III spine implant is substantial due to the stringent regulatory requirements set by the U.S. Food and Drug Administration (FDA). Here’s a breakdown of the estimated costs in GBP:
Total Development Cost: An economic evaluation study estimated the mean development cost for a novel complex medical device, such as a Class III spine implant, at approximately £41.58 million (95% CI, £19.25 million–£154 million) before post-approval studies (PASs). When including PASs, the cost rises to about £46.2 million (95% CI, £20.79 million–£160.93 million). When capitalized to account for the cost of capital and potential failures, the expected cost can escalate to £401.94 million (95% CI, £157.85 million–£2604.14 million) without PASs, and £405.02 million (95% CI, £159.39 million–£2614.92 million) with PASs. These figures include nonclinical (37%), clinical (60%), and FDA PMA stage (3%) costs.
FDA Fees: For fiscal year 2025, the FDA’s standard PMA application fee is approximately £371,910 for large businesses. Small businesses (with gross receipts or sales below £77 million) may qualify for a reduced fee of about £93,170 by submitting FDA Form 3602 (or 3602A for non-U.S. companies).
Breakdown of Costs:
Nonclinical Stage: Includes preclinical research such as bench and animal testing, accounting for roughly 37% of the total cost (~£15.4 million on average).
Clinical Stage: Involves feasibility and pivotal clinical trials, constituting about 60% of the cost (~£24.95 million on average). The median cost per clinical study is around £4.62 million (95% CI, £0–£6.16 million).
FDA PMA Stage: Covers the application process, including data compilation and submission, making up about 3% of the cost (~£1.23 million, excluding the FDA fee).
Post-Approval Studies (PASs): If required, PASs add an estimated £4.62 million to the total cost to ensure continued safety and effectiveness post-market.
Additional Considerations:
The process can take years, with an average FDA review time of 180–320 days depending on whether an advisory committee is involved.
Costs can vary significantly based on the complexity of the device, the scope of clinical trials (e.g., patient enrollment, typically around 297–500 patients), and whether the manufacturer opts for a modular PMA submission to spread costs over time.
Additional expenses may include quality management system (QMS) implementation, manufacturing audits, and post-market surveillance, which are not always fully quantified in the above estimates.
Some companies, like Empirical Spine for their LimiFlex™ Dynamic Sagittal Tether™, have noted that minimally invasive devices may reduce costs by enabling outpatient procedures, but specific cost savings for PMA are not detailed.
Context
Sign In
Follow the stocks
